| All patients | Glucocorticoid dose (by 2.5 mg/day increments) | |||
---|---|---|---|---|---|
0 mg/day | > 0 mg/day ≤ 2.5 mg/day | > 2.5 mg/day ≤ 5 mg/day | > 5 mg/day ≤ 7.5 mg/day | ||
Variables | N = 175 | N = 29 | N = 24 | N = 92 | N = 30 |
Glucocorticoid, median IQR, mg/day | 4.0 [2.0–5.0] | 0.0 [0.0–0.0] | 1.8 [1.0–2.0] | 5.0 [4.0–5.0] | 6.0 [6.0–7.0] |
Age, median IQR, years | 47.0 [37.0–61.0] | 44.0 [35.0–61.0] | 49.0 [38.0–64.5] | 47.5 [36.0–59.0] | 47.0 [39.0–58.0] |
Sex, female, n (%) | 157 (89.7) | 24 (82.8) | 22 (91.7) | 83 (90.2) | 28 (93.3) |
Damage index (SDI), median IQR, point | 0.0 [0.0–1.0] | 0.0 [0.0–0.0] | 0.0 [0.0–1.0] | 0.0 [0.0–1.0] | 0.5 [0.0–1.0] |
Time since SLE diagnosis, median IQR, year | 12.0 [6.0–19.0] | 10.0 [5.0–16.0] | 11.0 [6.5–19.0] | 12.0 [7.0–20.0] | 15.0 [7.0–22.0] |
Disease activity index (SLEDAI-2 K), median IQR, point | 2.0 [0.0–4.0] | 2.0 [1.0–4.0] | 2.0 [0.5–4.0] | 2.0 [0.0–4.0] | 2.0 [0.0–2.0] |
Hydroxychloroquine, n (%) | 46 (26.3) | 3 (10.3) | 5 (20.8) | 24 (26.1) | 14 (46.7) |
Number of Immunosuppressants | |||||
 1, n (%) | 78 (44.6) | 7 (24.1) | 6 (25.0) | 50 (54.3) | 15 (50.0) |
 2, n (%) | 15 (8.6) | 3 (10.3) | 2 (8.3) | 5 (5.4) | 5 (16.7) |
Immunosuppressants | |||||
 Cyclophosphamide, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Mycophenolate mofetil, n (%) | 15 (8.6) | 2 (6.9) | 2 (8.3) | 7 (7.6) | 4 (13.3) |
 Mizoribine, n (%) | 12 (6.9) | 1 (3.4) | 3 (12.5) | 6 (6.5) | 2 (6.7) |
 Methotrexate, n (%) | 3 (1.7) | 1 (3.4) | 0 (0.0) | 1 (1.1) | 1 (3.3) |
 Azathioprine, n (%) | 15 (8.6) | 0 (0.0) | 1 (4.2) | 11 (12.0) | 3 (10.0) |
 Tacrolimus, n (%) | 53 (30.3) | 8 (27.6) | 3 (12.5) | 28 (30.4) | 14 (46.7) |
 Cyclosporine, n (%) | 10 (5.7) | 1 (3.4) | 1 (4.2) | 7 (7.6) | 1 (3.3) |
Antipsychotics, n (%) | 10 (5.7) | 0 (0.0) | 2 (8.3) | 5 (5.4) | 3 (10.0) |
History of diagnosis | |||||
 Neuropsychiatric lupus, n (%) | 6 (3.4) | 2 (6.9) | 1 (4.2) | 2 (2.2) | 1 (3.3) |
 Lupus nephritis, n (%) | 38 (21.7) | 6 (20.7) | 3 (12.5) | 23 (25.0) | 6 (20.0) |